Galactorrhea: Causes, Symptoms, Diagnosis, and Treatment

What is Galactorrhea?

Non-puerperal galactorrhea is a medical condition defined as the production and secretion of a milky fluid from the breast outside of the normal physiological context of breastfeeding or the postpartum period. The term combines the Greek words gala (milk) and rhoia (flow), literally meaning “milk flow”.

It is critically important to understand that galactorrhea is a symptom, not a disease in itself. Its presence signals that an underlying condition, whether hormonal, pharmacological, neurological, or otherwise, is causing the mammary glands to produce milk inappropriately. Identifying and addressing that underlying cause is the cornerstone of management.

While galactorrhea is most commonly associated with women of reproductive age, it can affect:

• Women of all ages, including postmenopausal women
• Men
• Newborns and infants

The condition ranges in significance from entirely benign and self-resolving (as in neonatal galactorrhea) to an indicator of a pituitary tumor or other serious pathology requiring specific treatment.

Understanding Normal Milk Production

To understand galactorrhea, it helps to briefly review how lactation normally works. The primary hormone responsible for milk production is prolactin, secreted by specialized cells (lactotrophs) in the anterior pituitary gland. Under normal circumstances, prolactin levels are kept relatively low outside of pregnancy and breastfeeding through the inhibitory effect of dopamine, a neurotransmitter released by the hypothalamus that continuously suppresses prolactin secretion.

During and after pregnancy, high levels of estrogen and progesterone stimulate lactotroph proliferation and prolactin secretion. After delivery, the removal of placental hormones allows prolactin to act on the breast, initiating milk production. Suckling by the infant further stimulates prolactin release through a neuroendocrine reflex.

Galactorrhea almost always indicates a disruption in this system. Specifically, it results from elevated prolactin levels (hyperprolactinemia), which can occur through several mechanisms described below.

---

Causes

The most clinically important and common pathophysiological cause of galactorrhea is hyperprolactinemia, which refers to an abnormally elevated level of prolactin in the bloodstream. Any condition or substance that either directly increases prolactin secretion or blocks the inhibitory effect of dopamine on the pituitary can cause hyperprolactinemia and, consequently, galactorrhea.

Prolactinoma

Prolactinoma, a benign prolactin-secreting adenoma of the pituitary gland, is the most common pituitary tumor. It is also the most frequently identified pathological cause of galactorrhea and hyperprolactinemia.

Prolactinomas are classified by size:

• Microprolactinoma: This form has a diameter of less than 10 mm. It is the most common type, especially in women. May produce significant hyperprolactinemia and galactorrhea despite being very small.
• Macroprolactinoma: A tumor with a diameter of 10 mm or greater. This type is more common in men. Can cause local mass effects in addition to hyperprolactinemia.

Prolactinomas account for approximately 30–40% of all clinically identified pituitary adenomas. They are almost invariably benign and very rarely undergo malignant transformation.

Beyond galactorrhea, prolactinomas can cause symptoms through two mechanisms:

1. Excess prolactin: The hormonal effects described in the Symptoms section
2. Local mass effect: As the tumor grows, it may compress adjacent structures:
   • Optic chiasm: Causing characteristic bitemporal hemianopia (loss of the outer half of the visual field in both eyes)
   • Adjacent normal pituitary tissue: Causing panhypopituitarism (deficiency of multiple pituitary hormones)
   • Cavernous sinus: Causing cranial nerve palsies (diplopia, facial numbness)
   • Headaches from dural stretching

Medications

Drug-induced galactorrhea is among the most common causes overall. However, it is often overlooked unless a careful medication history is taken. The mechanism involves pharmacological blockade of dopamine receptors or reduction of dopamine availability, releasing the pituitary lactotrophs from inhibitory control and allowing prolactin levels to rise.

The major medication classes associated with galactorrhea and hyperprolactinemia include:

• Antipsychotic medications (neuroleptics). All typical antipsychotics (haloperidol, chlorpromazine, fluphenazine) and many atypical antipsychotics (risperidone, amisulpride, sulpiride) block dopamine D2 receptors with high affinity, producing significant and often symptomatic hyperprolactinemia. This is one of the most common drug-induced causes of galactorrhea. Some atypical antipsychotics (clozapine, quetiapine, aripiprazole, olanzapine) have less prolactin-elevating effects.

• Antidepressants. Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, sertraline, citalopram, paroxetine, and escitalopram can elevate prolactin through serotonergic pathways that stimulate prolactin release. Tricyclic antidepressants also have this effect. Drug-induced galactorrhea from antidepressants is typically mild compared to antipsychotics.

• Metoclopramide and domperidone (anti-nausea agents). These prokinetic and antiemetic medications act as dopamine antagonists and are potent stimulators of prolactin release. Metoclopramide is one of the most reliably galactorrhea-inducing drugs in clinical use.

• Antihypertensive medications. Methyldopa (a centrally acting antihypertensive that reduces dopamine synthesis) and less commonly verapamil (a calcium channel blocker) are associated with elevated prolactin.

• Combined oral contraceptive pill. The estrogen component of combined oral contraceptives stimulates pituitary lactotroph proliferation and may elevate prolactin modestly. Galactorrhea attributed to the pill is usually mild and often persists for several months after discontinuation.

• Opioid analgesics. Both exogenous opioids (morphine, codeine, oxycodone, methadone) and endogenous opioid peptides suppress hypothalamic dopamine release, thereby disinhibiting prolactin secretion. Chronic opioid use is a recognized cause of hyperprolactinemia.

• Antiulcer medications. Cimetidine and ranitidine (H2 receptor blockers, now largely replaced by proton pump inhibitors) can elevate prolactin. Proton pump inhibitors are not significantly associated with hyperprolactinemia.

• Other medications associated with galactorrhea include: tricyclic antidepressants, risperidone, methadone, sumatriptan, and some antihistamines.

Excessive Nipple and Breast Stimulation

Prolonged or repeated stimulation of the nipples and breast tissue activates the same neuroendocrine reflex arc that drives lactation during breastfeeding. This process triggers prolactin release from the pituitary. Causes include:

• Frequent breast self-examination beyond normal monthly checks
• Habitual nipple manipulation or picking
• Repetitive friction from tight clothing, sports bras, or wetsuits
• Sexual activity involving sustained nipple or breast stimulation
• Post-surgical stimulation after breast procedures
• Chronic irritation from clothing or jewelry

In these cases, reducing the frequency of stimulation often resolves the galactorrhea without any other intervention.

Hypothalamic and Pituitary Lesions

Any structural lesion affecting the hypothalamic-pituitary axis can disrupt the normal dopaminergic inhibition of prolactin:

• Pituitary stalk section or compression: Any lesion that disrupts dopamine flow from the hypothalamus to the pituitary, also called the “stalk effect”, can lead to disinhibited prolactin secretion. Common causes are craniopharyngiomas, meningiomas, metastases, sarcoidosis, and histiocytosis.
• Pituitary apoplexy: Sudden hemorrhage or infarction within the pituitary gland.
• Traumatic brain injury: Particularly injuries affecting the hypothalamus or pituitary stalk.
• Pituitary surgery or radiation: May impair normal hypothalamic-pituitary regulation.
• Empty sella syndrome: Herniation of the arachnoid membrane into the pituitary fossa, compressing pituitary tissue.

Associated Medical Conditions

Several systemic diseases can cause or contribute to galactorrhea through effects on prolactin metabolism or pituitary function:

• Chronic renal failure (CKD). The kidneys are responsible for clearing prolactin from the circulation. In chronic kidney disease, impaired renal clearance allows prolactin to accumulate, causing hyperprolactinemia and potentially galactorrhea. This is most significant in patients on hemodialysis.

• Hypothyroidism. An underactive thyroid gland causes elevated levels of TRH (thyrotropin-releasing hormone). Besides stimulating TSH, this hormone also directly stimulates prolactin secretion. Primary hypothyroidism is therefore a recognized cause of mild-to-moderate hyperprolactinemia and galactorrhea. Correcting hypothyroidism with levothyroxine typically normalizes prolactin levels.

• Liver cirrhosis. The liver normally metabolizes and clears estrogens and other hormones. In cirrhosis, impaired hepatic metabolism causes accumulation of estrogens, which stimulate pituitary lactotrophs and contribute to hyperprolactinemia. Cirrhosis also causes reduced dopamine clearance.

• Epilepsy and seizures. Prolactin levels surge dramatically (often 3–4 fold above baseline) in the immediate postictal period following generalized tonic-clonic seizures. This postictal prolactin elevation is sufficiently reliable and specific that it is used clinically to help distinguish true epileptic seizures from psychogenic non-epileptic attacks (PNEA). Chronic epilepsy itself, and some antiepileptic medications, can cause persistent mild hyperprolactinemia.

• Chest wall trauma and surgery. Injury, inflammation, or surgical procedures involving the chest wall (including mastectomy, thoracotomy, or herpes zoster affecting the thoracic dermatomes) can trigger galactorrhea through stimulation of afferent neural pathways that mimic the suckling reflex.

Stress

Psychological and physiological stress can transiently elevate prolactin levels through activation of stress-response neuroendocrine pathways (including the hypothalamic-pituitary-adrenal axis). Stress-induced hyperprolactinemia is usually mild and temporary. However, it may contribute to galactorrhea in susceptible individuals, especially when other contributing factors are present.

Idiopathic Galactorrhea

In many patients, especially women with normal or only slightly elevated prolactin levels, no identifiable cause is found even after a thorough investigation. This is termed idiopathic galactorrhea. It is believed to reflect:

• Heightened breast tissue sensitivity to normal prolactin levels
• Subclinical prolactin elevation not consistently detectable on standard testing
• Subtle disruptions of the dopaminergic regulatory system

Idiopathic galactorrhea often resolves spontaneously over time.

Galactorrhea in Men

Although galactorrhea primarily affects women, it can also occur in men. In such cases, it is always clinically significant and requires thorough investigation.

The mechanisms in men are:

Hyperprolactinemia from the same causes as in women All the conditions and medications described above can cause galactorrhea in men. In men, prolactinoma is relatively more likely to be a macroprolactinoma (large tumor) at the time of diagnosis, because the typical symptoms in women (menstrual irregularities, galactorrhea) prompt earlier medical attention, while the equivalent male symptoms (erectile dysfunction, reduced libido) may be attributed to other causes and go uninvestigated for longer.

Reduced testosterone Testosterone normally exerts a mild inhibitory effect on prolactin secretion. Hypogonadism (from any cause) can therefore contribute to relative hyperprolactinemia. Additionally, low testosterone directly reduces breast tissue suppression. In men, galactorrhea is often accompanied by gynecomastia, a benign enlargement of breast glandular tissue, due to hormonal imbalance.

Other symptoms of hyperprolactinemia in men include:

• Erectile dysfunction
• Reduced libido and sexual desire
• Infertility (from suppression of gonadotropin secretion)
• Loss of body and facial hair
• Reduced muscle mass
• Gynecomastia

Galactorrhea in Newborns

A small, milky secretion from the nipples of newborns, sometimes called “witch’s milk”, is a well-recognized and entirely physiological phenomenon. It occurs in about 5% of newborns, regardless of sex.

The mechanism is straightforward: throughout pregnancy, the mother’s high levels of estrogen and progesterone (both of which stimulate breast tissue development and prime the lactotrophs) cross the placental barrier and circulate in the fetal bloodstream. These maternally-derived hormones stimulate the fetal breast tissue, preparing it for potential lactation. At birth, the infant experiences a temporary phase of relative hyperprolactinemia once separated from the placental hormone supply. This happens because the sudden removal of high estrogen and progesterone eliminates their inhibitory effect, a process similar to what occurs in the mother after childbirth.

This transient neonatal galactorrhea:

• Is self-limiting. It resolves spontaneously within a few weeks as maternal hormone levels decline in the neonatal circulation.
• Requires no treatment.
• Should not be expressed by squeezing the nipple, as this can introduce infection (neonatal mastitis).

If neonatal nipple discharge is persistent, bloody, or associated with signs of infection (redness, warmth, swelling), medical evaluation is warranted.

Risk Factors

The following factors increase the likelihood of developing galactorrhea:

• Female sex: Significantly more common in women, reflecting both the greater breast tissue sensitivity to prolactin and the greater hormonal fluctuations of the female reproductive system.
• Age 20–35 years: The peak reproductive years, when hormonal influences are greatest.
• History of previous pregnancies and breastfeeding: Prior lactation may predispose breast tissue to respond to lower prolactin thresholds.
• Use of prolactin-elevating medications: Particularly antipsychotics, metoclopramide, and SSRIs.
• Known pituitary or hypothalamic conditions.
• Chronic kidney or liver disease.
• Hypothyroidism (untreated or undertreated).

---

Symptoms

As noted, galactorrhea is itself a symptom rather than a disease. Its core manifestation is the production and discharge of a milky, white or clear secretion from one or both nipples in the absence of recent pregnancy or breastfeeding.

Characteristics of the Discharge

The discharge in galactorrhea may be:

Spontaneous or induced

• Spontaneous: The milk leaks without any physical stimulation of the breast, staining undergarments or clothing.
• Provoked: The discharge appears only when the nipple is squeezed or the breast is pressed. At other times, no discharge is visible.

Unilateral or bilateral

• Bilateral (both breasts): More commonly associated with systemic causes of hyperprolactinemia (medications, prolactinoma, systemic disease)
• Unilateral (one breast only): May be more suggestive of a local breast pathology, though bilateral causes can produce unilateral presentation

Variable in quantity From a few drops expressed only with pressure, to spontaneous, continuous leaking

Associated Symptoms from Hyperprolactinemia

Because galactorrhea is most commonly a sign of elevated prolactin, it often occurs alongside the broader clinical effects of hyperprolactinemia. These effects vary between women and men.

In women:

• Amenorrhea (complete absence of menstruation): Prolactin suppresses GnRH, or gonadotropin-releasing hormone. This suppression reduces the secretion of LH and FSH, the pituitary hormones responsible for driving the menstrual cycle and ovulation.
• Oligomenorrhea (infrequent or irregular periods)
• Vaginal dryness and dyspareunia (painful intercourse): Resulting from hypoestrogenism caused by prolactin-mediated suppression of ovarian estrogen production
• Anovulation and infertility: Inability to conceive due to absence of ovulation
• Decreased libido
• Breast tenderness and engorgement

In men:

• Erectile dysfunction: Prolactin suppresses testosterone production through hypothalamic effects.
• Reduced libido and sexual desire.
• Gynecomastia: Benign breast enlargement from estrogen-testosterone imbalance.
• Infertility: From suppressed spermatogenesis.
• Reduced body and facial hair, reduced muscle mass.

In both sexes (particularly with prolactinoma):

• Headache: From dural stretching or elevated intracranial pressure as the tumor grows.
• Visual disturbances: Particularly bitemporal hemianopia, or outer visual field loss, caused by chiasmal compression from a macroprolactinoma. Patients often describe this as difficulty seeing objects to the sides without turning the head.
• Infertility.
• Osteoporosis: Prolonged hypoestrogenism (in women) or hypogonadism (in men) from hyperprolactinemia leads to reduced bone density and increased fracture risk.

---

Dangers and Prognosis

Prognosis

The prognosis of galactorrhea is almost entirely determined by its underlying cause. In general:

• Medication-induced galactorrhea: This condition typically resolves once the offending medication is discontinued or replaced. Improvement often occurs within weeks to months.
• Idiopathic galactorrhea: Frequently resolves spontaneously, sometimes without any specific intervention
• Hypothyroidism-related galactorrhea: Resolves with appropriate levothyroxine treatment as thyroid function is restored and TRH levels normalize
• Prolactinoma: Responds excellently to medical treatment with dopamine agonists (see Treatment section); surgical treatment is reserved for drug-resistant or very large tumors. Prognosis for fertility restoration is generally good with appropriate treatment.
• Stress-related galactorrhea: Improves with stress management

Even when galactorrhea resolves without treatment, medical evaluation is always recommended to identify the underlying cause, exclude serious pathology, and address any associated consequences (bone density loss, infertility, hormonal deficiencies).

Important Warning: Non-Milky Nipple Discharge

Galactorrhea, by definition, produces a milky white or clear, non-bloody secretion. Any nipple discharge that differs from this description requires urgent evaluation to exclude breast malignancy:

• Bloody discharge: Red or brown tinged. This is most commonly caused by intraductal papilloma, a benign tumor within a breast duct, but it must be evaluated to exclude ductal carcinoma in situ (DCIS) or invasive breast cancer.
• Greenish or brownish discharge: Associated with fibrocystic changes or duct ectasia.
• Yellow, purulent discharge: May indicate infection (mastitis, breast abscess).
• Clear watery discharge: Can be associated with early breast cancer.

If nipple discharge is not milky white, particularly if it appears bloody, greenish, or watery, it should be evaluated immediately to rule out breast cancer.

Additionally, nipple discharge occurring in a postmenopausal woman warrants thorough investigation regardless of its character, as breast malignancy is more common in this age group.

Consequences of Prolonged Hyperprolactinemia

If hyperprolactinemia remains untreated for an extended period, significant health consequences can accumulate:

• Bone density loss (osteoporosis). The hypoestrogenism in women (and hypogonadism in men) caused by chronic hyperprolactinemia is a potent stimulus for bone resorption. Over years, this leads to a progressive reduction in bone mineral density. As a result, the risk of fragility fractures increases, especially in the vertebrae and hip.

• Infertility. Persistent anovulation in women and impaired spermatogenesis in men prevent natural conception. Treatment of hyperprolactinemia typically restores fertility in both sexes.

• Cardiovascular risk. Prolonged estrogen deficiency in premenopausal women increases the risk of adverse cardiovascular events and metabolic changes.

• Pituitary apoplexy (in untreated large prolactinomas). A rare but potentially life-threatening complication in which a pituitary tumor suddenly hemorrhages or infarcts, causing rapid expansion and compression of adjacent structures. Presents with a sudden, severe headache, visual loss, and altered consciousness: this is a neurosurgical emergency.

---

Diagnosis

The diagnostic evaluation of galactorrhea aims to:

1. Confirm the presence of true galactorrhea (as opposed to other nipple discharge)
2. Identify the underlying cause
3. Assess the extent of any associated hormonal dysfunction

Medical History and Physical Examination

A thorough medical history (anamnesis) is the essential foundation:

• Duration of galactorrhea and whether it is spontaneous or provoked
• Character of the discharge (color, consistency)
• Laterality (one or both breasts)
• Menstrual history (cycle regularity, amenorrhea, oligomenorrhea)
• Current medications (including all prescription and over-the-counter drugs and supplements)
• Recent pregnancy, breastfeeding, or chest surgery
• Symptoms of hypothyroidism (constipation, fatigue, cold intolerance, dry skin)
• Symptoms of hyperprolactinemia (visual changes, headaches, sexual dysfunction)
• History of kidney or liver disease, epilepsy

Physical examination includes:

• Assessment of the discharge (character, whether spontaneous or expressible)
• Breast examination for masses, skin changes, lymphadenopathy
• Visual field assessment (confrontation testing) for optic chiasm compression
• Assessment of signs of hypothyroidism, chronic liver disease, or other systemic conditions
• In men: assessment of gynecomastia and testicular size

Pregnancy Test

A pregnancy test is the mandatory first step for any woman of reproductive age who presents with galactorrhea. Before proceeding with further investigation, it is essential to rule out physiological lactation caused by an unrecognized pregnancy.

Analysis of the Discharge

Microscopic examination of expressed nipple fluid can confirm the milky, lipid-rich character of true galactorrhea (rich in fat droplets on microscopy) and exclude blood, inflammatory cells, or malignant cells.

Blood Tests

Key laboratory investigations include:

• Serum prolactin: The central investigation. Importantly, prolactin levels fluctuate and may be acutely elevated by stress, nipple stimulation, food, or exercise. Therefore, a single modestly elevated result should be confirmed with a repeat sample collected under standardized resting conditions. Multiple elevated samples (particularly > 200 ng/mL) are very suggestive of prolactinoma.
• TSH and free thyroid hormones: To exclude hypothyroidism as a contributing cause
• Testosterone (in men): Assessing for hypogonadism
• LH and FSH: To assess gonadotropin status and distinguish primary from secondary hypogonadism
• Renal function tests (creatinine, eGFR): To assess for chronic kidney disease
• Liver function tests: To assess for cirrhosis or hepatic dysfunction
• IGF-1 and growth hormone: If acromegaly is suspected (which can coexist with pituitary pathology)
• Morning cortisol and ACTH stimulation test: If adrenal insufficiency is suspected (coexisting pituitary dysfunction)

Imaging Investigations

• Breast ultrasound and/or mammography. Indicated when the character of the discharge raises concern for a local breast pathology, particularly when discharge is bloody, watery, or unilateral. Helps exclude intraductal papilloma, ductal carcinoma in situ, or invasive breast cancer.

• Brain MRI (Magnetic Resonance Imaging) with gadolinium contrast. The investigation of choice for imaging the pituitary gland when a prolactinoma or other pituitary/hypothalamic lesion is suspected. Dedicated pituitary MRI protocols with thin slices and gadolinium contrast are required, as standard brain MRI may miss small microprolactinomas. MRI defines tumor size, extent, relationship to the optic chiasm, and involvement of the cavernous sinuses.

• CT scan (TAC). An alternative when MRI is contraindicated (e.g., certain metallic implants, severe claustrophobia). Less sensitive than MRI for detecting small pituitary adenomas but adequate for identifying macroprolactinomas and bony erosion.

• Visual field testing (perimetry). Formal automated visual field testing (Humphrey or Goldman perimetry) is essential when a macroprolactinoma with optic chiasm proximity is identified on imaging, to document and monitor chiasmal compression.

---

Treatment

Since galactorrhea is a symptom of an underlying condition, treatment is directed at the root cause. The appropriate therapeutic approach therefore depends entirely on the diagnosis.

Medication-Induced Galactorrhea

When galactorrhea is identified as a side effect of a medication:

• Discontinue or switch the offending drug where clinically feasible, ideally in consultation with the prescribing physician. This should never be done unilaterally, particularly for psychiatric medications where abrupt discontinuation may be dangerous.
• If the causative medication cannot be stopped (e.g., essential antipsychotic treatment), dose reduction may help if clinically appropriate.
• Alternative medications with less prolactin-elevating potential may be substituted (e.g., aripiprazole or quetiapine instead of risperidone for antipsychotic therapy).
• Galactorrhea typically resolves within weeks to months of medication change.

Hypothyroidism-Related Galactorrhea

Treatment with levothyroxine to normalize thyroid function generally restores normal prolactin levels and resolves galactorrhea within weeks to months of achieving euthyroidism.

Prolactinoma Treatment

Dopamine agonists are the first-line and most effective treatment for prolactinomas of any size, as they directly restore the dopaminergic inhibition of prolactin secretion:

• Cabergoline (Dostinex)

  • The preferred agent for most patients. Taken once or twice weekly, it is more effective, better tolerated, and requires less frequent dosing than bromocriptine. Normalizes prolactin in over 85–90% of patients with microprolactinomas. Also causes tumor shrinkage in the majority of macroprolactinomas. Even very large tumors may shrink dramatically with medical treatment alone, sometimes avoiding the need for surgery.

• Bromocriptine (Parlodel)

  • The older agent, taken daily. Still used in some clinical contexts, including when cabergoline is unavailable or when pregnancy is desired (bromocriptine has the longest safety record in pregnancy).

Dopamine agonist treatment typically:

• Normalizes prolactin levels within weeks.
• Restores ovulation and menstrual cycles in the majority of women, making pregnancy possible.
• Causes tumor shrinkage in most prolactinomas. Even large tumors that compress the optic chiasm may show remarkable reduction in size.
• Resolves galactorrhea within weeks to months.
• Resolves visual field defects in many patients with chiasmal compression.

Duration of treatment: Dopamine agonist therapy is typically maintained for a minimum of 2 years. After this period, patients with microprolactinomas who have achieved normalized prolactin levels and radiological regression of the tumor may attempt gradual dose reduction and potential discontinuation. This should be done under close monitoring, as about 20–30% of patients with microprolactinomas can maintain long-term remission after drug withdrawal.

Surgery (transsphenoidal resection). Surgical removal of the prolactinoma through a transsphenoidal (through the nose and sphenoid sinus) approach is considered when:

• The patient is intolerant of or resistant to dopamine agonists
• There is a cystic tumor or CSF leak requiring decompression
• The tumor is very large with significant mass effect causing acute neurological deterioration
• The patient prefers surgical cure

Radiotherapy: Used as a third-line option when surgery and dopamine agonists have both failed or are contraindicated. Stereotactic radiosurgery (Gamma Knife) is preferred for residual or recurrent tumor.

Galactorrhea from Nipple Stimulation

When excessive nipple stimulation is identified as the cause:

• Patient education and reassurance.
• Reduction in frequency of self-examination.
• Avoidance of behaviors or clothing that cause repetitive friction.
• Most cases resolve spontaneously once the stimulus is removed.

Idiopathic Galactorrhea

When no specific cause is identified:

• Reassurance: idiopathic galactorrhea is benign.
• Observation and periodic monitoring of prolactin levels
• Low-dose dopamine agonist therapy may be offered to patients who find the galactorrhea distressing
• Often resolves spontaneously over time

Galactorrhea and Fertility

For women with hyperprolactinemia-related galactorrhea and amenorrhea who wish to conceive, treatment with dopamine agonists (typically bromocriptine, given its longer pregnancy safety record) restores ovulation in the majority of cases, making natural conception possible. Dopamine agonists are generally discontinued once pregnancy is confirmed, as the tumor rarely grows significantly during pregnancy in women with microprolactinomas.

Management of Bone Density Loss

In patients with significant or prolonged hyperprolactinemia and confirmed hypogonadism, monitoring and management of bone mineral density (DEXA scan) is important. Restoring normal sex hormone levels through effective prolactin treatment is the primary intervention; supplemental calcium, vitamin D, and in some cases bisphosphonate therapy may be appropriate for established osteoporosis.

---

Summary

Galactorrhea, which refers to milk secretion outside of pregnancy and breastfeeding, is a clinically meaningful symptom. It is almost always caused by hyperprolactinemia. Its causes are diverse, ranging from entirely benign (medication side effect, nipple stimulation, idiopathic) to conditions requiring specific treatment (prolactinoma, hypothyroidism, renal failure). In men and neonates, the condition has distinct features and causes.

The key clinical messages are:

1. Always evaluate galactorrhea medically. Do not dismiss it without investigation.
2. Exclude pregnancy first in women of reproductive age.
3. Review all medications, as drug-induced galactorrhea is common and often missed.
4. Measure serum prolactin and TSH as initial blood tests.
5. MRI of the pituitary is required when prolactin is significantly elevated.
6. Non-milky discharge requires urgent breast imaging to exclude malignancy.
7. Dopamine agonists are highly effective and the treatment of choice for prolactinoma.
8. Untreated hyperprolactinemia causes long-term consequences including bone loss and infertility.

Sources and Bibliography

• MedlinePlus – U.S. National Library of Medicine. Galactorrhea.
• Mayo Clinic. Galactorrhea: Symptoms and Causes.
• Endocrine Society. Hyperprolactinemia: Clinical Practice Guideline.
• Melmed S., Casanueva F.F., Hoffman A.R., Kleinberg D.L., Montori V.M., Schlechte J.A., Wass J.A.H. Diagnosis and Treatment of Hyperprolactinemia. Journal of Clinical Endocrinology & Metabolism, 2011.
• NHS. Prolactinoma.